findmyKOL
Clinical trialNCT03278782Active, not recruitingPhase 1/PHASE2Interventional

Study of Pembrolizumab (MK-3475) in Combination With Romidepsin

SponsorM.D. Anderson Cancer CenterEnrollment39Recurrent Anaplastic Large Cell LymphomaRecurrent Angioimmunoblastic T-Cell LymphomaRecurrent Mature T- and NK-Cell Non-Hodgkin LymphomaRecurrent Mycosis FungoidesRecurrent Primary Cutaneous T-Cell Non-Hodgkin LymphomaRefractory Anaplastic Large Cell Lymphoma+5 more conditions
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • M D Anderson Cancer Center

    Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
14 Nov 2017
Primary completion
31 Jul 2027
Completion
31 Jul 2027
Last update posted
9 Jan 2026
Registered enrollment
39
Registry id
NCT03278782
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.